Baxter International: Debt, Margin Pressure, Dreadful FY26 Guidance (Downgrade) (NYSE:BAX)

Core Viewpoint - Baxter International Inc. experienced a significant decline in share price following disappointing Q4 results and a negative FY 2026 guidance, indicating potential challenges ahead for the company in the Healthcare Equipment industry [1]. Financial Performance - The company's market capitalization is currently $9.6 billion, reflecting a downturn in investor confidence [1]. - Baxter's stock is trading at a single-digit price-to-earnings ratio, suggesting that the market may be undervaluing the company or anticipating further difficulties [1]. Future Outlook - The FY 2026 guidance provided by Baxter is described as "ugly," which raises concerns about the company's growth prospects and operational performance in the coming years [1].